Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P29084
UPID:
T2EB_HUMAN
Alternative names:
General transcription factor IIE subunit 2
Alternative UPACC:
P29084; D3DSV2; Q9H2B9
Background:
Transcription initiation factor IIE subunit beta, also known as General transcription factor IIE subunit 2, plays a pivotal role in the recruitment of TFIIH to the initiation complex. It enhances the RNA polymerase II C-terminal domain kinase and DNA-dependent ATPase activities of TFIIH, essential for promoter clearance by RNA polymerase.
Therapeutic significance:
Linked to Trichothiodystrophy 6, a condition without cutaneous photosensitivity, this protein's malfunction due to genetic variants underlines its critical biological function. Understanding the role of Transcription initiation factor IIE subunit beta could open doors to potential therapeutic strategies for this multisystem disorder.